Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis

Myelofibrosis (MF) is a clonal Philadelphia negative myeloproliferative neoplasm that is associated with cytopenias, splenomegaly, a heterogeneous symptom profile, and decreased overall survival.[1][1] Accurate prognostication of MF is essential for clinical decision making, as survival estimates